Bend Bioscience

🗓️ Join us on August 6th for Endpoints News Manufacturing Day! 🗓️ Our very own Owen Murray will be part of the expert virtual panel "Battling Wildfires in Pharma Supply Chains: CDMO Leaders Weigh In." Discover how the industry can enhance partnerships with CDMOs to revolutionize supply chains, ensuring more predictable cost-efficiency and global accessibility.🌍 Don't miss out on this insightful discussion moderated by Orientation Marketing's Elliott Berger. 🎤 Secure your spot now. Register here: 👉https://lnkd.in/g4gFcrDR See you there! 🌟 #ManufacturingDay #CDMO #SupplyChain #Biopharma #EndpointsNews

Bend Bioscience is happy to be featured in the recent The Pharma Navigator article, “From Complex APIs to Patient-Centricity: The Power of Oral Dosage Innovation.” Our CSO, David Vodak, shares how advanced formulation technologies are solving drug delivery challenges and improving patient outcomes. David highlights enabling approaches such as spray-dried dispersions, multiparticulate systems, and modified-release platforms. These technologies address poor solubility and help design oral dosage forms that are easier to take, taste better, and deliver consistent therapeutic effects. At Bend Bioscience, we partner with clients to move from early-phase concepts to commercial-ready oral solid dose products by combining deep formulation expertise with scalable manufacturing solutions. Read the full article here: https://lnkd.in/gPAptjXd #OralDosage #FormulationScience #PatientCentricity #CDMO #PharmaInnovation

Who's heading to #CRS2025? Bend Bioscience is attending and we look forward to connecting with you. Michael Grass and Gordon Davis will be there, so send them a DM or schedule a meeting in advance here: https://lnkd.in/gyweCcE2 Don't miss Gordon's poster presentation! (#459) Early Phase Selection of a Controlled Release Amorphous Dispersion Formulation Overview: Currently it is estimated that over 50% of compounds in discovery and early development have poor water solubility and will require an enabling formulation technology to achieve efficacious exposure levels (1). Combining the use of amorphous solid dispersion formulation and a controlled release profile of that supersaturated solubility. For early phase screening, an in vitro test methodology was developed to evaluate (i) the stability of the amorphous form in the controlled release dosage form matrix, and (ii) the extent of supersaturation maintained after release from the dosage form. Learning Objectives: - Understand the profile that require amorphous dispersion formulations with controlled release -Explain in vitro testing methodology and in silico model to screen ASD formulations within a CR DF - Relate the interplay of model and in vitro inputs during early formulation screening

Bend Bioscience’s Rachel L. Timberlake, MBA and Marinn Hersh will be in Boston and ready to connect with innovators tackling complex drug development challenges. From enabling bioavailability for poorly soluble compounds with spray drying, to advancing modified-release oral solid dose formulations, to navigating the path from preclinical to commercial manufacturing, our team thrives on solving tough scientific problems. If your program needs: ✅ Expertise in particle engineering and amorphous solid dispersions ✅ Integrated development and GMP manufacturing support ✅ Flexible capacity and a collaborative CDMO partner …this is the perfect time to start the conversation. Send Rachel or Marinn a DM or book a time here: https://lnkd.in/gyweCcE2 #CDMO #DrugDevelopment #PharmaManufacturing #HighScienceHighService

We Are Pleased to Announce Our Collaboration with Starton Therapeutics!   “Bend Bioscience is committed to improving patients’ lives by delivering innovative drug products. This collaboration underscores our commitment to supporting our partners from early development through commercial production. Our reputation for progressing medicines to clinical and commercial manufacturing is a testament of our commitment to strong science, exceptional quality, and positive outcomes for our customers and their patients. We are excited to be a part of Starton’s story, and to see STAR-LLD potentially reach patients in need.” - Owen Murray, CEO   -------   Press Release, June 24, 2025 -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, today announced a collaboration agreement with Bend Bioscience (“Bend”), a leading innovation, science, and pharmaceutical services partner, whereby Bend will provide drug delivery R&D support and manufacturing capabilities for Starton’s lead candidate, STAR-LLD, a proprietary oral sustained release dosage form of lenalidomide. Click here to read the full release: https://lnkd.in/gVfipP2e

Faster timelines. Smarter collaboration. Real public health impact. The FDA’s CNPV program is a game-changer for companies developing high-priority therapies. At Bend Bioscience, we’re ready to help our partners move faster, with confidence. Read our take here: By: Cara Young

Will you be attending the Gordon Research Conferences Preclinical Form and Formulation for Drug Discovery? The team from Bend Bioscience will be there & are looking forwarding to an exciting week in Portland, Maine. 🦞 If you are attending, let us know - we'd love to connect! "Looking forward to the chance to connect with others in the industry who are passionate about tackling formulation challenges. It’s a great opportunity to share ideas, hear what others are working on, and come away with fresh insights that can help shape how we approach early drug formulation development." - Zach Martin "I am most excited for the session on using in silico and in vitro tools for formulation design with talks from Amitava Mitra, PhD, FAAPS (Kura Oncology, Inc.), Sandra Suarez-Sharp (Simulations Plus, Inc.), and Rebecca Carrier (Northeastern University). I am interested to learn more about how they are using predictive tools to enable more efficient and targeted formulation design." -Kiana Kawamura If you're attending, make sure to check out Kiana's poster on Partition-Driven Controlled Release for Oral Formulations of Spray Dried Dispersions!

If you're based in the New York area, our team would love to connect! Cara Young and Michael Boyle from Bend Bioscience will be in NYC on June 25/26 and are available for meetings. Whether you're interested in the latest changes to FDA National Priority review vouchers, want to hear about our U.S.-based development and manufacturing capabilities, or or just need a CDMO partner with capacity to get started quickly, we’re here for it. Send Cara or Mike a DM or book a time here: https://lnkd.in/gyweCcE2 #BendBioscience #CDMO #DrugDevelopment #PharmaManufacturing #SprayDrying #HighScienceHighService

PRESS RELEASE  --------- Clearwater, FL. – June 19, 2025 – Bend Bioscience, a leading innovation, science, and pharmaceutical services partner, today announced the opening of four new process development and manufacturing suites within its 30,000-square-foot site in Bend, Oregon. The suites will support spray drying and unit operations including granulation, encapsulation, compression and coating for oral dosage forms, and includes a dedicated low humidity suite for inhalation powder encapsulation and moisture-sensitive powder handling.   Read the full release here: https://lnkd.in/g27-bewZ     #BendBioscience #SprayDriedDispersions #SDD #DrugDevelopment #CDMO

Bend Bioscience is driving innovation with High Science + High Service. With expanded operations in Bend, Oregon, Clearwater, Florida and Gainesville, Georgia, Bend Bioscience is redefining what it means to be a next-generation contract development and manufacturing organization (CDMO). Focused on solving complex oral and inhaled drug delivery challenges, we blend cutting-edge science with collaborative service models to support innovators from early development through commercial scale-up. Contract Pharma sat down with our CEO, Owen Murray, to discuss the company’s growth, its role in the evolving drug product landscape, and how we are helping partners translate scientific breakthroughs into real-world therapies. Read the full article here: https://lnkd.in/gPkvcD4z #CDMO #DrugDevelopment #PharmaceuticalManufacturing #ContractPharma